115 related articles for article (PubMed ID: 7380909)
21. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
22. Gas chromatography and mass spectrometry of N-(phosphonacetyl)-L-aspartic acid.
Branfman AR; Valia KH; Bruni RJ
J Chromatogr; 1978 Apr; 151(1):71-4. PubMed ID: 641126
[No Abstract] [Full Text] [Related]
23. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
[No Abstract] [Full Text] [Related]
24. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
25. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
26. m-AMSA and PALA: two new agents in cancer chemotherapy.
Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
[TBL] [Abstract][Full Text] [Related]
28. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
White JC; Hines LH
Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
[TBL] [Abstract][Full Text] [Related]
29. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper ES; Vale K; Williams LJ; Martin DS; Young CW
Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
[TBL] [Abstract][Full Text] [Related]
31. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Sharma A; Straubinger NL; Straubinger RM
Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
[TBL] [Abstract][Full Text] [Related]
32. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
Harrison SD; Giles HD; Denine EP
Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
[No Abstract] [Full Text] [Related]
33. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
34. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Creagan ET; O'Connell MJ; Kovach JS
Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
[TBL] [Abstract][Full Text] [Related]
35. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Kim JS; Heath TD
Arch Pharm Res; 2000 Apr; 23(2):167-71. PubMed ID: 10836745
[TBL] [Abstract][Full Text] [Related]
36. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
37. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
39. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
